AMR report depicts industry commitment
Medicines for Europe is among the healthcare industry stakeholders who have welcomed the first report on antimicrobial resistance (AMR) by the AMR Industry Alliance, which “brings together over 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations from 20 countries” and shows that “broadly the Alliance membership is already active and making positive contributions to the challenge of AMR”.
You may also be interested in...
Generics firms have a crucial role to play in the fight against antimicrobial resistance, Thomas Cueni, chair of the AMR Industry Alliance, tells Generics Bulletin in an exclusive interview.
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.
The Swiss pharma giant is building momentum in radiopharmaceuticals by racking up positive pivotal trial data and overcoming manufacturing bottlenecks.